Mobile-Based Telemedicine as a Milestone for Lifestyle Monitoring Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis

Main Article Content

Sena Pongtuluran
Jaun Alessandro Jeremis Maruli Nura Lele
Fanessa Pingkan Widytri Nugroho

Abstract

Introduction:


NAFLD is the most common liver disease worldwide which can progress to fibrosis, cirrhosis, liver failure, hepatocellular carcinoma, and death. Currently, there is no therapeutic treatment and non-adherence to lifestyle modifications still possess problems. Diet and exercise are the main treatment for patients with NAFLD. Mobile-based telemedicine provides a powerful approach to dealing with behavioral changes.


Objective:


The study aims to assess the efficacy of mobile-based telemedicine in improving liver function and body weight among NAFLD patients.


Method:


The literature search was performed using PubMed, Plos One, Proquest, EBSCO Essentials, Wiley, and Cochrane using the keyword: Non-alcoholic fatty liver disease, smartphone, and telemedicine. The data was screened based on inclusion and exclusion criteria. Risk of bias assessment was done using ROB 2.0 tool. Meta-analysis was done using Review Manager 4.1 to measure the mean difference of AST, ALT, and weight improvement.


Results:


Five randomized controlled trials with a 513 total number of participants were included. Overall study considered as low risk of bias. The meta-analysis showed AST, ALT and weight improvement with MD -9.68 (random effect; 95 % CI -16.48 to -2.88; P = 0.005), MD -19.72 (random effect; 95 % CI -32.26 to -7.18; P = 0.002), and MD -2.34 (fixed effect; 95% CI -3.52 to -1.15; P = 0.0001) respectively.

Conclusion:


Mobile-based telemedicine has been proved to significantly improve liver function by reducing AST and ALT levels and body weight in NAFLD patients.

Article Details

How to Cite
Pongtuluran, S., Jaun Alessandro Jeremis Maruli Nura Lele and Fanessa Pingkan Widytri Nugroho (2022) “Mobile-Based Telemedicine as a Milestone for Lifestyle Monitoring Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis”, Journal of Asian Medical Students’ Association. Kuala Lumpur, Malaysia. Available at: https://jamsa.amsa-international.org/index.php/main/article/view/466 (Accessed: 3December2022).
Section
Scientific Posters (EAMSC 2023 Nepal)

References

REFERENCES

Axley P, Kodali S, Kuo YF, Ravi S, Seay T, Parikh NM, et al. Text Messaging approach improves weight loss in patients with non alcoholic fatty liver disease: A randomized study. Liver International. 2017;38(5):92-931

Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49(2):197-211

Javanmardifard S, Ghidsbin F, Kaviani MJ, Jahanbin I. The effect of telenursing on self-efficacy in patients with non alcoholic fatty liver disease: a randomized controlled clinical trial. Gastroenterol Hepatol Bed Bench. 2017;10(4):263-271

Lim SL, Johal J, Ong KW, Ha nCY, Chan YH, Lee YM, et al. Lifestyle intervention enabled by mobile technology on weight loss in patients with nonalcoholic fatty liver disease: Randomized controlled trial. JMIR Mhealth Uhealth. 2020;8(4):14802

Mazzotti A, Caletti MT, Brodosi L, Di DS, Forchielli ML, Petta S, et al. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. J Hepatol. 2018;69(5):1155-1163

Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher, G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020, 111S, 154170.

Holmer, Magnus et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomized controlled trial. JHEP Reports. 2021;3 (3)

Mauro E, Marciano S, Torres MC, Roca JD, Novillo AL, Gadano A. Telemedicine Improves Access to Hepatology Consultation with High Patient Satisfaction. J Clin Exp Hepatol. 2020;10(6):555-562.

Siopis G, Chey T, Allman-Farinelli M. A systematic review and meta-analysis of interventions for weight management using text messaging. Journal of Human Nutrition and Dietetics. 2015; 18(2)1-15

Hall AK, Cole-Lewis H, Bernhardt JM. Mobile text messaging for health: a systematic review of reviews. Annu Rev Public Health. 2015;36:393-415

Safavi M, Yahyavi H, Purheydari M. Effects of feeding behaviors and exercise activities training on the efficacy of Middle school students. Med Sci J Islamic Azad Univ Tehran Med Branch. 2012;22:143-51

Parker S, Prince A, Thomas L, et al. Electronic, mobile and telehealth tools for vulnerable patients with chronic disease: a systematic review and realist synthesis. BMJ Open. 2018;8:e019192

Serper, M., Cubell, A.W., Deleener, M.E., Casher, T.K., Rosenberg, D.J., Whitebloom, D. and Rosin, R.M. Telemedicine in Liver Disease and Beyond: Can the COVID-19 Crisis Lead to Action?. Hepatolgy. 2020;72(2):723-8

Shidfar F, Bahrololumi SS, Doaei S, Mohammadzadeh A, Gholamalizadeh M, Mohammadimanesh A. The effects of extra virgin olive oil on alanine aminotransferase, aspartate aminotransferase, and ultrasonographic indices of hepatic steatosis in nonalcoholic fatty liver disease patients undergoing low calorie diet. Canadian journal of gastroenterology and hepatology. 2018 Apr 17;2018.

Karim SM, Rahman MR, Shermin S, Sultana R. Correlation between aminotransferase ratio (AST/ALT) and other biochemical parameters in chronic liver disease of viral origin. Delta Medical College Journal. 2015 Feb 14;3(1):13-7.

Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC endocrine disorders. 2022 Dec;22(1):1-9.

Brunner KT, Henneberg CJ, Wilechansky RM, Long MT. Nonalcoholic fatty liver disease and obesity treatment. Current obesity reports. 2019 Sep;8(3):220-8.

Schwimmer JB, Ugalde-Nicalo P, Welsh JA, et al. Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial. JAMA. 2019;321(3):256–265.

Sakane N, Kotani K, Suganuma A, Takahashi K, Sato J, Suzuki S, Izumi K, Kato M, Noda M, Nirengi S, Kuzuya H. Effects of obesity, metabolic syndrome, and non-alcoholic or alcoholic elevated liver enzymes on incidence of diabetes following lifestyle intervention: A subanalysis of the J-DOIT1. J Occup Health. 2020 Jan;62(1):e12109.

Ghodsbin F, Javanmardifard S, Kaviani MJ, Jahanbin I. Effect of tele-nursing in the improving of the ultrasound findings in patients with nonalcoholic fatty liver diseases: A Randomized Clinical Trial study. Invest. Educ. Enferm. 2018; 36(3):e09.

Guarino M, Cossiga V, Fiorentino A, Pontillo G, Morisco F. Use of Telemedicine for Chronic Liver Disease at a Single Care Center During the COVID-19 Pandemic: Prospective Observational Study. J Med Internet Res. 2020;22(9):e20874

Stotts MJ, Grischkan JA, Khungar V. Improving cirrhosis care: The potential for telemedicine and mobile health technologies. World J Gastroenterol. 2019;25(29):3849-3856.

Fard SJ, Ghodsbin F, Kaviani MJ, Jahanbin I, Bagheri Z. The Effect of Follow up (Telenursing) on ​​Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. Int J Community Based Nurses Midwifery. 2016;4(3):239-246

Hoffer-Hawlik MA, Moran AE, Burka D, Kaur P, Cai J, Frieden TR, Gupta R. Leveraging Telemedicine for Chronic Disease Management in Low- and Middle-Income Countries During Covid-19. Global Hearts. 2020 Sep 15;15(1):63

Abid Haleem, Mohd Javaid, Ravi Pratap Singh, Rajiv Suman. Telemedicine for healthcare: Capabilities, features, barriers, and applications. Sensors Internasional. 2021; 2: 2666-3511